Journal of hepato-biliary-pancreatic sciences
-
J Hepatobiliary Pancreat Sci · Jan 2016
Impact of postoperative changes in sarcopenic factors on outcomes after hepatectomy for hepatocellular carcinoma.
We have reported that preoperative low skeletal muscle quality was an independent risk factor for poor outcomes after hepatectomy for hepatocellular carcinoma (HCC). However, postoperative changes of quality as well as quantity of skeletal muscle after hepatectomy for HCC and their impact on postoperative outcomes have not been fully investigated. ⋯ Postoperative depletion of skeletal muscle quality is closely involved with HCC recurrence after hepatectomy for HCC.
-
J Hepatobiliary Pancreat Sci · Dec 2015
Comparative StudyLaparoscopy-assisted pancreaticoduodenectomy as minimally invasive surgery for periampullary tumors: a comparison of short-term clinical outcomes of laparoscopy-assisted pancreaticoduodenectomy and open pancreaticoduodenectomy.
Few reports have described laparoscopy-assisted pancreaticoduodenectomy (LAPD) as an alternative to the conventional open approach for periampullary tumors. The safety and feasibility of this procedure remain to be determined. In this study, we compared the short-term clinical outcomes of LAPD with those of open pancreaticoduodenectomy (OPD). ⋯ LAPD is a technically safe and feasible alternative treatment for periampullary tumors, with short-term clinical outcomes equivalent to those of OPD, with a shorter hospital stay.
-
J Hepatobiliary Pancreat Sci · Nov 2015
Randomized Controlled Trial Multicenter StudyEfficacy of preoperative dexamethasone for postoperative nausea and vomiting after laparoscopic cholecystectomy: a large-scale, multicenter, randomized, double-blind, placebo-controlled trial in Japan.
To assess the efficacy of preoperative dexamethasone for postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy (LC) in Japan. ⋯ Routine use of preoperative dexamethasone for PONV after elective LC in Japan was not shown to have a clinical advantage.
-
J Hepatobiliary Pancreat Sci · Nov 2015
Multicenter Study Clinical TrialFeasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
The aim of this multi-institutional study was to assess the feasibility and the efficacy of gemcitabine plus cisplatin (CDDP) combination therapy (GC therapy) for biliary tract cancer (BTC) in the adjuvant setting. ⋯ Standard dose of GC therapy is tolerable in patients with BTC who underwent curative resection either with or without major hepatectomy. The survival effect of this regimen is promising, but further comparative study is needed.
-
J Hepatobiliary Pancreat Sci · Nov 2015
ReviewLaparoscopic living donor hepatectomy: a review of current status.
Over the last two decades, laparoscopic surgery has been adopted in various surgical fields. Its advantages of reduced blood loss, reduced postoperative morbidity, shorter hospital stay, and excellent cosmetic outcome compared with conventional open surgery are well validated. In comparison with other abdominal organs, laparoscopic hepatectomy has developed relatively slowly due to the potential for massive bleeding, technical difficulties and a protracted learning curve. ⋯ However, the number of cases is too small to validate the safety and reproducibility. The most important concern in LDLT is donor safety. Even though a few studies reported the technical feasibility and comparable outcomes to conventional open surgery, careful validating through larger sample sized studies is needed to achieve standardization and wide application.